Plain-English translation of NCT05872204 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combined with can help people with rare types of ovarian cancer that have come back or spread. Both medications work to slow or stop cancer growth, and they have shown promise together in breast cancer treatment. Researchers are studying whether this same combination might work better than alone for certain rare ovarian cancers.
Many people with rare, hormone-sensitive ovarian cancers have limited treatment options after their cancer returns. This medication combination has worked well for similar hormone-sensitive breast cancers, so doctors want to see if it could offer new hope for ovarian cancer patients who need alternatives to chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would take as capsules twice daily and as a tablet once daily in 28-day cycles, continuing until your cancer progresses, you experience unacceptable side effects, or another reason to stop. You would have regular visits for monitoring, imaging scans to track your cancer, and blood tests. You would also be asked to provide tissue biopsies before starting and during treatment, as well as blood samples for research to help doctors understand why some people respond better to this treatment than others.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Belgium
France